INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 121 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2017. The put-call ratio across all filers is 0.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $5,000 | +400.0% | 150 | 0.0% | 0.00% | – |
| Q3 2019 | $1,000 | -50.0% | 150 | 0.0% | 0.00% | – |
| Q2 2019 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
| Q1 2019 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
| Q4 2018 | $2,000 | -33.3% | 150 | 0.0% | 0.00% | – |
| Q3 2018 | $3,000 | 0.0% | 150 | 0.0% | 0.00% | – |
| Q2 2018 | $3,000 | 0.0% | 150 | 0.0% | 0.00% | – |
| Q1 2018 | $3,000 | +50.0% | 150 | 0.0% | 0.00% | – |
| Q4 2017 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
| Q3 2017 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
| Q2 2017 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
| Q1 2017 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
| Q4 2016 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
| Q3 2016 | $2,000 | -66.7% | 150 | 0.0% | 0.00% | – |
| Q2 2016 | $6,000 | +50.0% | 150 | 0.0% | 0.00% | – |
| Q1 2016 | $4,000 | -50.0% | 150 | 0.0% | 0.00% | – |
| Q4 2015 | $8,000 | +33.3% | 150 | 0.0% | 0.00% | – |
| Q3 2015 | $6,000 | – | 150 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |